# Medicare opens door to covering blockbuster drugs for weight loss - CNN

## Metadata
| Field | Value |
|-------|-------|
| Source | CNN |
| URL | https://news.google.com/rss/articles/CBMidEFVX3lxTE56eWo1MHp0azJrMDhRSUxHR3NJWGJMa1ZOWUlMV3djUDVxNlBHeE9rWUNLUWRBOXpvc2JBdU1nRTRidkw5WEdrNHQ4Zlpzb0wxRExZOTdwRHhtMTNYTU5qOFg3YzhFMDhQR0dhc1Bjb05CXzZZ?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 12:01 |
| Category | GLP-1|Policy|Regulatory |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
Medicare's potential coverage of weight loss drugs like Ozempic and Wegovy represents a massive market expansion for obesity treatments, signaling significant investment potential in GLP-1 therapeutics and related healthcare technologies.

## Key Entities
Medicare, Novo Nordisk, Eli Lilly

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1|policy|regulatory #auto-scraped
